Biofrontera submits supplemental NDA to expand Ameluz for full-body AK
Biofrontera said it has submitted a supplemental new drug application to the FDA to expand Ameluz® Red Light PDT for actinic keratoses on the full body.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Biofrontera submits supplemental NDA for Ameluz® full-body actinic keratoses
Biofrontera (BFRIW) submitted a supplemental new drug application to the FDA to expand Ameluz® red light PDT for actinic keratoses on the full body.